NCT04284761View on ClinicalTrials.gov

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 11, 2020

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Prostate AdenocarcinomaLower Urinary Tract Symptoms
Interventions
COMBINATION_PRODUCT

Bicalutamide implant

Biolen bicalutamide implant

Trial Locations (4)

2076

Australian Clinical Trials, Wahroonga

2500

University of Wollongong, Wollongong

3112

Tauranga Urology Research, Tauranga

20892

National Institutes of Health Clinical Center, Bethesda

Sponsors
All Listed Sponsors
lead

Alessa Therapeutics Inc.

INDUSTRY

NCT04284761 - A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter